


THE INNATE IMMUNITY COMPANY



R&D DAY 2018

LONDON, MARCH 8





FORWARD LOOKING STATEMENT

This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed.

This document contains forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to various risks and uncertainties, which could cause the Company’s actual results or financial condition to differ materially from those anticipated. Please refer to the risk factors outlined from time to time in the Company’s regulatory filings or publications.

This document contains data pertaining to the Company’s potential markets and the industry and environment in which it operates. Some of this data comes from external sources that are recognized in the field or from Company’s estimates based on such sources.

The information contained herein has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The Company is under no obligation to keep current the information contained in this presentation and any opinion expressed is subject to change without notice. The Company shall not bear any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

Please refer to the Document de Référence filed with the Autorité des Marchés Financiers (“AMF”) on March 31st, 2017, available on the AMF’s website (www.amf-france.org) and on the Company’s website (www.innate-pharma.com). Such documents may not be necessarily up to date.

This document and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares of the Company in any country.



TODAY'S SPEAKERS



Mondher
MAHJOUBI, MD,

**Chief Executive Officer
Innate Pharma**



Eric
VIVIER, DVM, PhD

**Chief Scientific Officer
Innate Pharma**



Pierre
DODION, MD, MBA,

**Chief Medical Officer
Innate Pharma**



Julia
SCARISBRICK, MD,

**Dermatologist & Lead,
Cutaneous Lymphoma
University Hospitals
Birmingham NHS
Foundation Trust**



Mohammed
DAR, MD,

**VP Clinical Development
Oncology,
AstraZeneca/MedImmune**



AGENDA

1

STRATEGY INTRODUCTION – MONDHER MAHJOUBI

2

BUILDING AN INNOVATIVE AND DIFFERENTIATED PIPELINE – ERIC VIVIER

3

PROPRIETARY PIPELINE – PIERRE DODION

- > IPH5401 – POTENTIAL TO UNLOCK THE IMMUNE RESPONSE
- > IPH4102 – NEW THERAPEUTIC OPTION FOR T-CELL LYMPHOMA – JULIA SCARISBRICK

4

PARTNERED PIPELINE

- > MONALIZUMAB – COMBINATION STRATEGY OPPORTUNITY – MOHAMMED DAR

5


MARKET POTENTIAL AND PIPELINE NEWSFLOW – MONDHER MAHJOUBI

6

Q&A

7

CLOSING REMARKS



STRATEGY INTRODUCTION

MONDHER MAHJOUBI
CHIEF EXECUTIVE OFFICER



KEY MESSAGES

World-class science and technology platform

Clinical read-outs ahead for monalizumab and IPH4102 programs

Delivering on IPH5401 with clinical collaborations to accelerate development

Potential to address large unmet medical needs in cancer

Financial strength, enabling room for investment



INNATE PHARMA – STRATEGY

SCIENCE DRIVEN ORGANIZATION AND PATIENT CENTRIC COMPANY

Strategic Priorities

Create **diverse** portfolio of **first** or **best-in-class** IO agents

Partner with leading IO companies to unlock the value of assets with substantial market potential

Retain more **value** in house and move toward **integrated** biopharma company



INNATE PHARMA – APPROACH

SCIENTIFIC EXCELLENCE AROUND 3 KEY PILLARS

1

**NK cells
checkpoints
(NKCP)**

2

**Tumor
targeting
(TA_g)**

3

**Tumor
Microenvironment
(TME)**



INNATE PHARMA – PIPELINE

FIRST-IN-CLASS IMMUNO-ONCOLOGY (IO) ASSETS

Target Discovery	Drug Discovery	Preclinical	Dose finding	Signal detection	Pivotal
~20 targets or concepts under exploration	Anti-Siglec-9	IPH52 Anti-CD39	IPH5401 Anti-C5aR	Monalizumab Anti-NKG2A	
	SAN-NKCE-2	IPH53 Anti-CD73		Lirilumab Anti-KIR2DL1,2,3	
	Other undisclosed targets	IPH4301 Anti-MICA/B		IPH4102 Anti-KIR3DL2	
		IPH61 SAN-NKCE-1			



INNATE PHARMA – PRIORITIES AND KEY CATALYSTS

Key Value Creation Steps 2018

- **Read-out of current clinical programs**
 - > Monalizumab w/ cetuximab in advanced SCCHN @AACR
 - > Monalizumab w/ durvalumab in solid tumors
 - > Cohort expansion data for IPH4102
- **Preparing next stages of clinical studies**
 - > IPH4102: lifting the full potential in T-Cell lymphomas beyond CTCL
 - > IPH5401 to enter the clinic in oncology in H2; clinical collaborations to secure full development opportunities potential in prioritized indications
 - > Finalize preclinical package for IPH52/53
- **Grow development portfolio, create next generation of product candidates**



FY2017 RESULTS

FINANCIAL STRENGTH, ENABLING INVESTMENTS IN FUTURE GROWTH

Revenue*: €44m

- Mainly from industrial partnerships

Op. expenses: €84m

- Increase in R&D expenses support clinical development of IPH4102 and monalizumab

Cash position: €177m

- 2017 cash burn €54m**
- Strong cash position to invest in development pipeline

*revenue and other income

** including milestone payment of €14m received in January 2017



BUILDING AN
INNOVATIVE AND
DIFFERENTIATED
PIPELINE

ERIC VIVIER
CHIEF SCIENTIFIC OFFICER



EXPERIENCE

30 YEARS IN ACADEMIC RESEARCH - IMMUNOLOGY

- D.V.M, PhD (Paris XI)
- Harvard Medical School



- Centre d'Immunologie de Marseille-Luminy



- Scripps, Rockefeller, WEHI



- European Research Council Laureate – Highly cited researcher



European Research Council
Established by the European Commission





EXPERIENCE

30 YEARS IN ACADEMIC RESEARCH - IMMUNOLOGY



MISSION

- Translating science into survival
- Finding new targets, new formats
- Identifying mechanisms of action



MEANS

- Expertise
- Technology
- Academic & industrial network




WHY INNATE PHARMA?

- World-class biotech company
- 4 first-in-class molecules in 15 years



CANCER: A GLOBAL CHALLENGE



In 2005, cancer accounted for 7.5 million of the 53.6 million deaths worldwide, meaning it accounted for **1 in 7 deaths.**




In 2015, cancer accounted for 8.8 million of the 55.8 million deaths worldwide, meaning it accounted for almost **1 in 6 deaths.**





THE IMMUNE SYSTEM

- CHALLENGES
- Microbial infections
 - Tumors



INNATE IMMUNITY



Naïve B&T
cells

ADAPTATIVE IMMUNITY

EFFECTOR RESPONSE

- Hours
- Whole body

- Days
- From lymphoid organs





A BRIEF HISTORY OF ANTI-TUMOR IMMUNOSURVEILLANCE



Figure 1. William B. Coley (1862-1930) lives there are long after his death. Coley is the founder of the World Center of the History of Medicine.

1891
New York City, USA
William Coley
'Coley toxine'



1967
Villejuif, France
Georges Mathé
BCG




Figure 1. Survival rates of patients with and without immunosurveillance. The solid line represents the survival rate of patients without immunosurveillance, and the dashed line represents the survival rate of patients with immunosurveillance. The x-axis represents time in days, and the y-axis represents survival rate in percent. The data shows that patients with immunosurveillance have a significantly higher survival rate than those without immunosurveillance.



1975
Bethesda, USA,
Steven A. Rosenberg
IL-2



1980
Bruxelles, Belgique
Thierry Boon
Tumor antigens



2001
Saint Louis, USA
Robert D. Schreiber
Tumor editing



1957
Melbourne, Australie
Sir MacFarlane Burnet
Tumor immunosurveillance



1996
Berkeley, USA
James P. Allison
CTLA-4




2002
Kyoto, Japon
Tasuku Honjo
PD-1






THE IMMUNO-ONCOLOGY REVOLUTION

DIRECT TARGETING OF TUMOR CELLS:
i.e. via tumor antigens



- Surgery
- Radiotherapy
- Chemotherapy

INDIRECT TARGETING OF TUMOR CELLS:
i.e. via immune checkpoints






THE MAB REVOLUTION IN CANCER IMMUNOTHERAPY

Resistant to chemo



Anti-PD1 mAbs



Baseline

12 weeks


24 weeks

52 weeks





WHAT'S NEXT IN IMMUNO-ONCOLOGY?



Immune Checkpoint Inhibitors

- anti-CTLA-4
 - > Ipilimumab (**YERVOY**, BMS)
 - > Tremelimumab (MEDIMMUNE-ASTRAZENECA)
- anti-PD-1
 - > Nivolumab (**OPDIVO**, BMS/ONO)
 - > Pembrolizumab (**KEYTRUDA**, MERCK)
- anti-PD-L1
 - > Avelumab (**BAVENCIO**, MERCK KGaA/PFIZER)
 - > Durvalumab (**IMFINZI**, MEDIMMUNE-ASTRAZENECA)
 - > Atezolizumab (**TECENTRIQ**, GENENTECH/ROCHE)



WHAT'S NEXT IN IMMUNO-ONCOLOGY?

- Understand the resistance to Immune Checkpoint Inhibitors
- Increase the fraction of patients sensitive to IO treatments
- Decrease toxicity
- Identify new targets (cells and molecules)
- Identify biomarkers



WHAT'S NEXT IN IMMUNO-ONCOLOGY?

- Understand the resistance to Immune Checkpoint Inhibitors
- Increase the fraction of patients sensitive to IO treatments
- Decrease toxicity
- **Identify new targets (cells and molecules)**
- Identify biomarkers





BROAD AND DIFFERENTIATED PORTFOLIO OF IO ASSETS

Target Discovery	Drug Discovery	Preclinical	Dose finding	Signal detection	Pivotal
~20 targets or concepts under exploration	Anti-Siglec-9	IPH52 Anti-CD39	IPH5401 Anti-C5aR	Monalizumab Anti-NKG2A	
	SAN-NKCE-2	IPH53 Anti-CD73		Lirilumab Anti-KIR2DL1,2,3	
	Other undisclosed targets	IPH4301 Anti-MICA/B		IPH4102 Anti-KIR3DL2	
		IPH61 SAN-NKCE-1			



BUILDING AN INNOVATIVE AND DIFFERENTIATED PIPELINE

Human surfaceome

20,000+ genes

35,000+ proteins

7,000+ proteins that can be expressed at the cell surface

Largely unexplored






Expression: Single cell genome-wide analysis



Function: Cell-based assays



Therapy: Best/First in class Ab generation





NEXT GENERATION IO

3 STRATEGIC KEY PILLARS TO HARNESS THE POTENTIAL OF IMMUNITY

1

**NK cells
checkpoints
(NKCP)**

2

**Tumor
targeting
(TAg)**

3

**Tumor
Microenvironment
(TME)**



NEXT GENERATION IO OUR STRATEGY

UNIQUE
POSITIONNING



FIRST-IN-CLASS
BEST-IN-CLASS




DIVERSIFIED
APPROACH





INNATE PHARMA – PIPELINE

TARGETING DIFFERENT STATUS OF THE IMMUNE RESPONSE



Adapted from Hedge et al., Clin Cancer Res, 2016



NEXT GENERATION IO

3 STRATEGIC KEY PILLARS

1

**NK cells
checkpoints
(NKCP)**

NKG2A

2

**Tumor
targeting
(TA_g)**


3

**Tumor
Microenvironment
(TME)**





ANTI-NKG2A IS A NOVEL IMMUNE CHECKPOINT INHIBITOR IN CANCER

- Monalizumab (IPH2201) is a first-in-class anti-NKG2A humanized blocking antibody



NK cell and T cell inhibition by NKG2A

+




Activation by NKG2A blockade




NKG2A / HLA-E PATHWAY IS UPREGULATED IN TUMORS

HLA-E on tumor cells



NKG2A on TILs





* underestimated because of few stroma in 5 tumors

- Score 3: > 76% positive cells
- Score 2: from 34 to 66% positive cells
- Score 1: between 1 and 33% positive cells
- Score 0: No positive cells



NKG2A/Q_A-1^b CONTROL TUMOR GROWTH



Individual A20 and A20 Qa-1^b KO and A20 PD-L1 KO tumor growth after sub-cutaneous engraftment of 5×10^6 A20 tumor cells (n=10) in BALB/C mice.

TF: Tumor Free, CR: Complete Regression


André et al. unpublished

innate pharma

NK cell checkpoints



PD-1^{HIGH} CD8⁺ TILs CO-EXPRESS NKG2A





Expression of NKG2A and PD-1 on isolated CD8⁺ TILs (day 20)


A20 B cell lymphoma into BALB/C mice



NKG2A AND PD-L1 BLOCKADES ARE COMPLEMENTARY




NK cell and T cell inhibition by NKG2A



Activation by NKG2A blockade



NKG2A BLOCKADE INCREASES PD-L1 ANTI-TUMORAL EFFICACY




RMA-Rae1 into B6 mice



P=0.03 (*), P=0.0006 (***), Grehan-Breslow-Wilcoxon test



NKG2A BLOCKADE ENHANCES ADCC IN A HLA-E⁺ CONTEXT




NK cell inhibition by NKG2A



ADCC enhancement by NKG2A blockade



NKG2A BLOCKADE ENHANCES CETUXIMAB-INDUCED ADCC OF H&N TUMOR CELLS





NEXT GENERATION IO

3 STRATEGIC KEY PILLARS

1

**NK cells
checkpoints
(NKCP)**

2

**Tumor
targeting
(TAg)**

**KIR3DL2
MICA/B
NKp46 NKCE**

3

**Tumor
Microenvironment
(TME)**



NEXT GENERATION IO

3 STRATEGIC KEY PILLARS

1

**NK cells
checkpoints
(NKCP)**

2

**Tumor
targeting
(TAg)**

KIR3DL2
MICA/B
NKp46 NKCE


3

**Tumor
Microenvironment
(TME)**




KIR3DL2 IS A TUMOR SPECIFIC ANTIGEN IN CTCL

- IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody





KIR3DL2 TARGETING INDUCES ANTI-TUMORAL EFFICACY





NEXT GENERATION IO

3 STRATEGIC KEY PILLARS

1

**NK cells
checkpoints
(NKCP)**

2

**Tumor
targeting
(TAg)**


**KIR3DL2
MICA/B
NKp46 NKCE**

3

**Tumor
Microenvironment
(TME)**



MICA/B IS INDUCED ON TUMOR CELLS AND DOWNREGULATES NKG2D






MICA/B CAN BE TARGETED BY NAKED AB OR ADC


Anti-MICA naked Ab

TRAMP-MICB tumor model



Anti-MICA-ADC

PDX (human breast)





NEXT GENERATION IO

3 STRATEGIC KEY PILLARS

1

**NK cells
checkpoints
(NKCP)**

2

**Tumor
targeting
(TAg)**

**KIR3DL2
MICA/B
NKp46 NKCE**


3

**Tumor
Microenvironment
(TME)**



NK CELL ENGAGER (NKCE) MULTISPECIFIC ANTIBODY TECHNOLOGY


- NKp46-NKCE binds to
 - > an antigen at the surface of tumor cells
 - > NKp46 activating receptor on NK cells and CD16 (FcγRIII)
- NKp46-NKCE may reduce the risk of side-effects associated with T cell engagers
- Library of proprietary anti-NKp46 mAbs and multispecific formats with PK and CMC advantages
- Opportunity for internal discovery NKCE targets as well as through collaboration






ANTI-CD20-NKP46-NKCE INDUCES ANTI-TUMORAL EFFICACY

In vitro



51Cr release assay / Resting NK cells vs Daudi

In vivo



CB17 SCID mice engrafted IV with Raji cells (5.10⁶) and treated at day1 with 1µg of compound.



NEXT GENERATION IO

3 STRATEGIC KEY PILLARS

1

**NK cells
checkpoints
(NKCP)**

2

**Tumor
targeting
(TA_g)**

3

**Tumor
Microenvironment
(TME)**

**Adenosine pathway
MDSC**



NEXT GENERATION IO

3 STRATEGIC KEY PILLARS

1

**NK cells
checkpoints
(NKCP)**

2

**Tumor
targeting
(TAg)**


3

**Tumor
Microenvironment
(TME)**

Adenosine pathway
MDSC




ADENOSINE PATHWAY IS IMMUNOSUPPRESSIVE IN THE TME



ATP : adenosine triphosphate **AMP** : adenosine monophosphate




CD39 EXPRESSION IN HEAD AND NECK TUMORS



CD39 is expressed on TILs and vascular endothelial cells



CD39 BLOCKADE INHIBITS BOTH ATP DEGRADATION AND ADENOSINE GENERATION





ATP : adenosine triphosphate AMP : adenosine monophosphate




LEAD ANTI-CD39 AB RESTORES IMMUNE RESPONSE IN THE PRESENCE OF ATP

T cell proliferation assay




● Anti-CD39
● IC

DC activation






CD39 AND CD73 EXPRESSION IN HEAD AND NECK TUMORS




CD39 is expressed on TILs and vascular endothelial cells



CD73 is expressed on tumor cells, TILs and vascular endothelial cells




CD39/CD73 BLOCKADE SYNERGIZE TO REVERSE ATP-MEDIATED T CELL SUPPRESSION





CD39/CD73 BLOCKADE AIMS AT REVERSING IMMUNOSUPPRESSION IN THE TME



ATP : adenosine triphosphate AMP : adenosine monophosphate



NEXT GENERATION IO

3 STRATEGIC KEY PILLARS

1

**NK cells
checkpoints
(NKCP)**

2

**Tumor
targeting
(TAg)**


3

**Tumor
Microenvironment
(TME)**

**Adenosine pathway
MDSC**




C5aR BLOCKADE INHIBITS MDSC/NEUTROPHIL RECRUITMENT AND ACTIVATION IN THE TME





C5AR/PD-1 BLOCKADE INDUCES TUMOR GROWTH INHIBITION IN A PD-1 RESISTANT MODEL





BROAD AND DIFFERENTIATED PORTFOLIO OF IO ASSETS

Target Discovery	Drug Discovery	Preclinical	Dose finding	Signal detection	Pivotal
~20 targets or concepts under exploration	Anti-Siglec-9	IPH52 Anti-CD39	IPH5401 Anti-C5aR	Monalizumab Anti-NKG2A	
	SAN-NKCE-2	IPH53 Anti-CD73		Lirilumab Anti-KIR2DL1,2,3	
	Other undisclosed targets	IPH4301 Anti-MICA/B		IPH4102 Anti-KIR3DL2	
		IPH61 SAN-NKCE-1			



THINK
BE CREATIVE
PROVIDE SOLUTIONS
OPENING



PROPRIETARY PORTFOLIO

PIERRE DODION
CHIEF MEDICAL OFFICER



NEXT GENERATION IO

3 STRATEGIC KEY PILLARS

1

**NK cells
checkpoints
(NKCP)**

2

**Tumor
targeting
(TAg)**

3

**Tumor
Microenvironment
(TME)**

IPH5401
(target: C5aR)




WHAT IS IPH5401?

- C5aR inhibitor: monoclonal antibody targeting the receptor (C5aR) to C5a
- C5a results from the cleavage of C5 as part of the complement cascade
- C5a stimulates the recruitment and functional activation of myeloid derived suppressor cells (MDSCs) and regulatory T-cells (Tregs)
 - > Leads to the inhibition of immune effector cells
- Inhibition of C5aR signaling was shown to increase CD8 T cell infiltration and function



MECHANISM OF ACTION IPH5401

ADDING A C5aR INHIBITOR RESTORES THE EFFICACY OF PD1/PDL1 BLOCKERS





IPH5401: PHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC DATA

Favorable safety profile in single & multi-dose, placebo controlled phase 1 trials in RA¹

	Single dose	Multiple dose
Dose range (mg/kg)	0.02-10 (iv) 0.2-4 (sc)	0.25-4 (sc)
Nr of pts (IPH5401/placebo)	27 / 9	18 / 6
% pts with AE (IPH5401/placebo) ²	67 / 44	78 / 50
Related AEs	3	4
RX discontinuation	0	0
Pts with anti drug antibodies	4 (0 neutralizing)	0
Full receptor occupancy	4.3 wks (10 mg/kg iv) 1.8 wks (4 mg/kg sc)	90% occupancy at 1-4 mg/kg Dose related duration

¹ RA: rheumatoid arthritis ² Most frequent AEs: nasopharyngitis, headache



PRIORITIZED INDICATIONS BASED ON C5aR EXPRESSION¹

Tumor type ¹	C5aR expression	Impact on prognosis
NSCLC	80%	Poor prognosis
UCC	73%	Poor prognosis
HCC	68%	Not known
CRC	60%	Not known
RCC	61%	Not known
Gastric cancer	30-35%	Poor prognosis
Prostate cancer	35%	Poor prognosis
Breast cancer	13%	Poor prognosis
TNBC	27%	

¹ Gu J et al. *Lung Cancer* 2013; 81:259-265. Hu W et al. *Exp Mol Pathol* 2016;100:101-8. Idorn M et al. *Cancer Immunol Immunother* 2014; 63:1177–87. Imamura T et al, *Breast Cancer* 2016; 23:876–85. Kaida T et al, *Oncotarget*, 2016;51:84798-809. Maeda Y et al, *Oncol Rep* 2015;33:1844-50. Nitta, H et al. *Clin Cancer Res* 2013; 19: 2004-13. Nitta H et al, *Med Oncol* 2016;33:118-27. Wada Y et al, *Oncol Lett* 2016; 12: 3995-4000



C5aR EXPRESSION NEGATIVELY IMPACTS LONG TERM OUTCOME IN NSCLC

C5aR expression impact on long term outcome in 208 previously untreated NSCLC





Fig. 3. Prognostic significance assessed by Kaplan-Meier survival estimates and log-rank tests. Comparisons of OS by CD88 expression in NSCLC (A), lung squamous cell carcinoma (B), and lung adenocarcinoma (C).

- The 5-year OS was significantly lower in high expressors of C5aR than in low expressors ($p = 0.001$)
- In a multivariate analysis, C5aR expression was an independent prognostic factor for patients' OS (HR = 1.614, 95% CI 1.082–2.407, $p = 0.019$)



An increase in C5aR expression by neutrophils is seen in NSCLC





PRIORITIZED INDICATIONS BASED ON MEDICAL NEED AND POTENTIALLY ACCELERATED PATH TO MARKET

Tumor type	Description of unmet medical need
NSCLC	- second line, post platinum: rate of long term failure as high as 80%: - first line: rate of long term failure of 30%
HCC	





PRIORITIZED INDICATIONS BASED ON MEDICAL NEED AND POTENTIALLY ACCELERATED PATH TO MARKET

Tumor type	Description of unmet medical need
NSCLC	• second line, post platinum: rate of long term failure as high as 80%: • first line: rate of long term failure of 30%
HCC	• second line post sorafenib

- Sorafenib: first targeted therapy to demonstrate activity in HCC
 - > ~ 3 months gain in OS; substantial toxicity
- Regorafenib:
 - > Again limited OS gain
- Nivolumab: phase 2 study in 262 sorafenib-pretreated patients
 - > 15% ORR; median duration of 17 months and median OS of 15 months
 - > 75% OS at 9 months
 - > Approved by FDA in 2017; withdrawn from EMA review
- Overall, HCC remains an unmet medical need – opportunity to augment the activity seen with nivolumab



ASTRAZENECA COLLABORATION TO ACCELERATE PROOF-OF-CONCEPT IN NSCLC AND HCC

	AstraZeneca/MedImmune Collaboration
Type of collaboration	Clinical agreement (access to drug, 50% trial cost sharing)
Tumor type for expansion cohorts	NSCLC 2 ^{ary} resistance (IO pretreated) IO naive HCC = unmet medical needs
PD1/PDL1 blockers sensitivity	Low
Partner drug	Durvalumab
Study design	Dose escalation Cohort expansion
Study start	2H18



SMART DEVELOPMENT PROGRAM WITH LIMITED DOSE-ESCALATING PART


- In combination with durvalumab
- Very limited dose escalation part
- Cohort expansion(s) at recommended phase 2 dose/schedule
- Indications selection: NSCLC, HCC
- Extensive PK/PD exploration (e.g. C5aR, C5a, MDSCs, CD8, PDL1, cytokines, TMB)




COMBINATION IPH5401 + DURVALUMAB

PROPOSED STUDY DESIGN

Dose escalation part: 3+3 model
primary endpoint: safety, RP2D




Cohort expansion part:
primary endpoint: ORR
(Simon 2-stage) design






PHASE 1 TO START 2H2018



All elements of study design and dates subject to validation.






ABUNDANT LIFE CYCLE OPPORTUNITIES

A COHERENT VISION OF MULTIPLE INDICATIONS, LINES OF THERAPIES AND DEGREE OF RESISTANCE

Tumor type	Setting
NSCLC	Secondary resistance to PD1/PDL1 blockers, in combination with durvalumab
HCC	PD1 naïve, in combination with durvalumab
UCC	IO untreated patients in combination with PD1/PDL1 agent





SUMMARY

1

Inhibition of C5aR signaling increases effector cell infiltration and function in the TME
Long-term failure rates of PD-1/L1 therapy create demand for combination strategies

2

Prioritization of indications based on C5aR expression and medical need
Clinical collaborations enhance program value
Smart study design accelerates Proof-of-concept
Limited dose-escalating part based on good tolerability

3

Substantial market potential across selected tumor indications



NEXT GENERATION IO

3 STRATEGIC KEY PILLARS

1

**NK cells
checkpoints
(NKCP)**

2

**Tumor
targeting
(TAg)**

IPH4102
(target: KIR3DL2)

3


**Tumor
Microenvironment
(TME)**



KIR3DL2 IS WIDELY EXPRESSED ON T CELL LYMPHOMAS

- KIR3DL2 is specifically expressed on cutaneous and circulating cutaneous T-cell lymphomas (CTCL) cells (various grades and subtypes):
 - > Expressed by ~65% of all CTCL patients
 - > Expressed by up to 85% of CTCL cells in certain aggressive subtypes, in particular Sézary Syndrome (SS) and transformed mycosis fungoides (tMF)
 - > Expressed by a subset of NK and T-cells
 - > Not expressed on other normal tissue
- Also expressed in PTCL (~50%) and ATLL (~80%)

SS pt, grade IIIB
87% KIR3DL2⁺ tumor cells¹



CTCL: cutaneous T cell lymphoma; PTCL: peripheral T cell lymphoma; ATLL: adult T cell leukemia/lymphoma

Battistella et al., 3WCCL poster 2016 1. Internal data



IPH4102: MODE OF ACTION

PROMISING ACTIVITY IN SÉZARY SYNDROME

- IPH4102 : first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody
- Designed to selectively destroy KIR3DL2-expressing CTCL cancer cells:
 - > upon binding to the receptor, the Fc domain of IPH4102 activates antibody dependent cell-mediated cytotoxicity (ADCC)
 - > antibody-dependent cell-mediated phagocytosis (ADCP) is also activated
- Good safety profile and promising activity demonstrated from a dose-escalating part of an ongoing Phase 1 study investigating IPH4102 in patients with Sézary Syndrome, an advanced form of CTCL




WHAT IS CTCL?

- Non Hodgkin's lymphoma, originating from T cells and with a tropism for the skin
- 4% of Non Hodgkin's Lymphoma
 - > ~ 1 / 100,000 (6,000 new cases for the US + EU)
 - > Rising annual incidence in US - ↑ by 2.9 per million per decade
- Clinically:
 - > Median age at diagnosis of 55-65 years
 - > Pronounced cutaneous involvement with debilitating pruritus
 - > Lymph nodes, viscera, and blood (Sézary Syndrome) may be involved
 - > Elevated risk of infections



EPIDEMIOLOGY OF CTCL (1)

Relative frequency of CTCL subtypes
per WHO-EORTC classification



Nr new cases/yr	5-yr overall survival
6,000	
3,300-3,900	20-95%
150-300	$\leq 15\%$
500-1000	76-96%
150-300	$\sim 10\%$
600	$\leq 20\%$


LPD: lymphoproliferative disorder. ALCL: anaplastic large cell lymphoma
ATL: Adult T cell lymphoma

Agar et al, JCO 2010; Kempf et al, Blood 2011; Willemze, Blood 1997; Willemze et al, Annals Oncol 2011; Kim et al, Arch Dermatol 2003




EPIDEMIOLOGY OF CTCL (2)

- Besides the histological subtypes, prognosis and survival of CTCL are strongly linked to **clinical stage**
- Other poor prognostic factors:** age >60 years, large cell transformation (LCT) in skin, increased Lactate Dehydrogenase (LDH) and extracutaneous involvement





TREATMENT OF CTCL OVERVIEW





STANDARDS OF CARE IN CTCL LIMITED TO MYCOSIS FUNGOIDES (AFTER FAILURE OF LOCAL THERAPIES)¹

	Preferred therapies
1 st line	Bexarotene, bexarotene-based combinations
2 nd line	Interferon, methotrexate, gemcitabine, liposomal-doxorubicin
3 rd line	Methotrexate, CHOP, palatrexate
4 th line	Romidepsin

Lines are softly defined in CTCL and physicians frequently interchange drugs sequence


¹ May further vary between stage IB-IIIB and > IIB



TREATMENT OF CTCL

NEW AGENTS WITH ACTIVITY: BRENTUXIMAB

- Brentuximab vedotin (Anti CD30 ADC):
 - > CTCL (CD30 positive; excl. SS): phase 3 study (ALCANZA) against investigator's choice (methotrexate/bexarotene) (128 pts)
 - > ORR4: 61 vs 8% ($p < 0.001$); med PFS: 15.8 vs 3.6 months (HR=0.37, $p < 0.001$)
 - > Polyneuropathy: 67% vs 6%; 14% RX discontinuation
 - > Drug approved by FDA and EMA





MOGAMULIZUMAB, A CCR4 INHIBITOR, IN CTCL

NEW AGENTS WITH ACTIVITY: MOGAMULIZUMAB

372 pts with MF or SS, in failure post ≥ 1 systemic therapy, randomized between mogamulizumab and vorinostat

Group ¹	PFS (mos) ^{1,2}	ORR	Toxicity
Mogamulizumab	7.7	28%	↑ Infusion related reaction, cutaneous toxicity
Vorinostat	3.1	5%	↑ nausea, diarrhea, fatigue, thrombocytopenia, decreased appetite, dysgueusia, renal
HR, p value	0.53 p< 0.0001		

¹ mos: months; HR: hazard ratio; ORR objective response rate

² Primary endpoint: PFS, using global composite response score based on skin, blood, lymph nodes, and viscera



STANDARDS OF CARE IN CTCL

HOW WILL MYCOSIS FUNGOIDES BE TREATED IN THE FUTURE?

KOLs opinion:

Bexarotene likely to stay the primary agent in 1st line (oral)
Strong impact of brentuximab & mogamulizumab in later lines



Predicted preferred therapies

1st line

Bexarotene, bexarotene-based combinations

2nd line

3rd line

Older drugs, brentuximab, and mogamulizumab competing in 2nd/3rd line

4th line

Still remaining a major unmet medical need



CTCL

FOUNDATIONS OF OUR CLINICAL DEVELOPMENT PLAN

- Single agent approach after 2 lines of prior systemic therapy, including biologics
- Multiple different subtypes with a variable prognosis
- Variable stages (IB-IV)
- Complex treatment algorithms
 - > Variable local therapies before reaching the stage of advanced CTCL
 - > May vary among institutions
- KIR3DL2 positivity
 - > About 60% overall
 - > And biologically viewed as essential for the efficacy of IPH4102

Supports a randomized program


Phase 2-3 design to explore biomarker strategy



CTCL

CLINICAL DEVELOPMENT PROGRAM¹

- Population: advanced after 2 lines of prior systemic therapies, including brentuximab / mogamulizumab
 - > Leveraging IPH4102 in patients with unmet medical need
- Randomized program of single agent IPH4102
- Comparator: investigator choice (gemcitabine, vorinostat)
- Phase 2 component to gauge the level of antitumor activity and to assess the need for KIR3DL2 positivity



Potential Biologics License Application. 1. All elements of study design and dates subject to validation.

IPH4102



SÉZARY SYNDROME

CLINICAL FEATURES AND SIMPLIFIED TREATMENT APPROACH

- Leukemic variant of CTCL – stage IV in all cases – poor prognosis
- Systemic therapy is the standard of care
- Older drugs/approaches
 - > First line setting: extracorporeal phototherapy, bexarotene, interferon α (combinations > single agent)
 - > Alemtuzumab, HDAC inh, older chemo agents in 2nd line
 - > Stem cell transplantation but usage limited due to age
- Mogamulizumab
 - > Subset of patients in the MAVORIC trial suffered from SS
 - > Clear improvement of PFS (HR = 0.32, $p < 0.0001$) and ORR (37 vs 2%)

SS: Sézary syndrome; HR: hazard ratio; ORR: objective response rate

EA Olsen, *J Am Acad Dermatol* 2011;64:352-404. Kim YH, et al.
ASH 2017. Abstract 817. NCCN Guidelines, 2017



SÉZARY SYNDROME

OVERALL TREATMENT APPROACH IN 2018



- ECP, bexarotene, Interferon α , Methotrexate, or combination of these approaches likely to stay the main approach in “1st line”
- Mogamulizumab likely to be approved (PDUFA date: June 4, 2018) and to penetrate the “2nd line” setting
- 3rd + line setting continues to represent a major unmet medical need
 - > Activity of comparators, including approved ones (e.g. HDAC inh) is low
 - > Toxicity is an area of great concern
 - > Symptom control is badly needed

IPH4102 has demonstrated great promise in these 3 areas, paving the way for a pivotal program in 3rd line SS



PIVOTAL PROGRAM IN SÉZARY SYNDROME

STUDY DESIGN – POTENTIAL ACCELERATED APPROVAL



Regulatory consultations

1. Preclinical data ☒
2. “Isolation” of SS ☒
3. ORR4 as 1^{ary} endpoint, PFS as key 2^{ary} endpoint ☒
4. Randomized design in small patient population using a calibration design ☒
5. Single arm approach under discussion, depending on cohort expansion data and mogamulizumab label ☐

Potential Biologics License Application. All elements of study design and dates subject to validation.


IPH4102



POTENTIAL DEVELOPMENT PATHS IN OTHER LYMPHOMAS

PTCL

- PTCL represent ~10% of all NHL WW
- Several subtypes with variable response to therapy and outcome
- ~ 50% express KIR3DL2



Standard of care

	PTCL	Incl. ALCL
1st line	Chemo (CHOP-like) at times followed by transplantation if possible	
2nd line*, Salvage options	Gemcitabine, oxaliplatin, palatrexate [§] , combination chemo (DHAP, GEMOX) romidepsin [§] , belinostat [§]	
		Brentuximab vedotin

*In Japan, mogamulizumab is approved in r/r CCR4-positive PTCL. [§] approved in the US only


In total, in contrast to B cell lymphomas, PTCL remains a major medical challenge



POTENTIAL DEVELOPMENT PATHS IN OTHER LYMPHOMAS

ATLL

- ATLL prevalence follows the distribution of the oncogenic HTLV-1 virus
 - > <10% of all PTCL WW (~25% in Japan)
 - > Annual incidence: WW: ~1,400; Japan: ~700-1,000
- Several subtypes with variable response to therapy and outcome
- KIR3DL2 expressed in ~ 80% of the patients



Standard of care

	Lymphoma	Acute
1 st line*	Chemo (CHOP-like) – Clin. trial	IFN, zidovudine – Clin. trial
	Consolidation for allo SCT	
2 nd + line*	No SOC	No SOC

*In Japan:

- Mogamulizumab is approved in 1st and 2nd lines.
- ~80-100 ATLL patients are transplanted each year.



CLINICAL DEVELOPMENT PLANS IN PTCL AND ATLL¹


- High interest of the medical community
- PTCL
 - > Preliminary IHC data showing positive KIR3DL2 in about 50% of the pts
 - > Preliminary preclinical data supporting a combination approach with chemotherapy
 - > Phase 2-3 program testing combination + IPH4102
- ATLL
 - > High prevalence of KIR3DL2 expression (>80%) in the acute form (most frequent and poorest prognosis)
 - > Opportunity identified in 1st line, probably in combination with chemo; objective to raise the CR rate prior to SCT
 - > 2 staggered programs (EU/US vs Japan)

¹ All elements of study design and dates subject to validation



CLINICAL DEVELOPMENT PLAN¹ ACROSS PATIENT POPULATIONS

SUMMARY



Potential Biologics License Application. 1. All elements of study design and dates subject to validation.

IPH4102



TARGETING KIR3DL2 IN CTCL

PHASE 1 DOSE ESCALATION



Dr. Julia Scarisbrick

MBChB, FRCP, MD

University Hospitals Birmingham NHS Foundation Trust

St Thomas Hospitals

The London Skin Clinic



SIGNS AND SYMPTOMS OF MYCOSIS FUNGOIDES (MF) AND SÉZARY SYNDROME (SS)

- General

- > Itching
 - > Disfigurement
 - > Pain
 - > Sleep disturbance
 - > Psycho-social disorders
-
- > High disease burden
 - > Quality of life impairment

Early Stages



plaques



Advanced Stages



tumors



erythroderma



THERAPIES IN EARLY-STAGE CTCL (PATCH/PLAQUE)

- Skin directed therapy
 - > No treatment shown to be superior
 - > Typically associated with short response duration
 - > 50-60% of patients will have recurrent disease
 - > Few durable complete responses
 - > Life expectancy may be normal
 - > Morbidity may be significant
 - > Improve symptoms and quality of life





THERAPIES IN ADVANCED-STAGE CTCL


- Chemotherapy (1970's)
- Immunotherapy (interferon 1980's)
- Extracorporeal photopheresis (1987)
- Novel retinoids (bexarotene 1999)
- Monoclonal antibody therapy (1997/2001/2017)
- Autologous / Allogeneic stem cell transplants (2000)
- Histone deacetylase inhibitors (2013)
(US: Vorinostat, Romidepsin)
- Treatment guidelines available from EORTC and NCCN¹

¹ EORTC: Eur Org for Research and Treatment of Cancer. NCCN: National Comprehensive Cancer Network



REAL-WORLD TREATMENT

Heterogeneity of treatment approaches were found, with up to 24 different modalities or combinations used as first-line and 31% of patients receiving 4 or more treatments



Modified from Quaglini et al, Ann Oncol. 2017



UNMET NEEDS IN CTCL

- Effective treatments
 - > Most have RR in 20-40%
 - > Most have short response duration 6-9 months
 - > Best combinations
- Effective symptom relief
 - > Patients have severe itch
 - > Sleep disturbance



SUMMARY TREATMENT GUIDELINES


- Early-stage CTCL should be treated with skin directed therapies
- Advanced-stage CTCL require systemic therapy
 - > No algorithm for treatment which is typically patient specific
 - > No regime proven to improve survival
 - > Most patients receive multiple consecutive therapies
 - > Evidence-based treatment options needed
- > Maintenance therapy to prolong progression free survival
- > Patients should be entered into clinical trials





KIR3DL2 IS A THERAPEUTIC TARGET IN CTCL

- KIR3DL2 belongs to the Killer Ig-like Receptor family that modulate NK and T cell activity
- KIR3DL2 is expressed on <10% normal T cells
- KIR3DL2 is widely expressed on CTCL cells (skin lesions and blood aberrant cells)
 - > Irrespective of disease clinical stage
 - > With a higher prevalence in Sézary syndrome (SS), CD30+ LPD and Mycosis fungoides with large-cell transformation
 - > KIR3DL2 may have prognostic significance in SS

Sézary syndrome



Transformed MF




Correlation between
KIR3DL2 and
TCR-Vβ expression
in Sézary syndrome
(n = 32)

**KIR3DL2 is
considered a
specific marker
of CTCL, high
therapeutic
index**




KIR3DL2 IS EXPRESSED ON MOST CTCL SUBTYPES




EID: erythrodermic inflammatory disease; MF: Mycosis Fungoides; SS: Sézary Syndrome; cALCL: primary cutaneous Anaplastic Large Cell Lymphoma; LyP: Lymphomatoid papulosis; HTLV1: (primary cutaneous) Human T-lymphotropic Virus positive T-cell lymphoma; TNK: extranodal NK-T cell Lymphoma; nos: not otherwise specified; subcut: subcutaneous panniculitis-like lymphoma; TCL: T-cell lymphoma; AETCL: aggressive epidermotropic T-cell lymphoma.



IPH4102-101 FIRST-IN-HUMAN PHASE 1 STUDY DESIGN AND OBJECTIVES



- Dose-escalation (10 dose levels – accelerated 3+3 design) followed by cohort expansion
- **Primary objective:** determination of Maximal Tolerated Dose (MTD) and Recommended Ph2 Dose (RP2D), overall safety
- **Secondary objectives:** clinical activity (criteria from Olsen et al 2011, JCO), PK/immunogenicity
- **Exploratory objectives:** changes in KIR3DL2+ cells in involved compartments
- **Key inclusion criteria:**
 - > Any CTCL subtype, ≥ 2 prior lines of systemic therapy, if MF/SS stage $\geq$ IB
 - > > 5% aberrant cells KIR3DL2pos in skin or blood
 - > Treatment until progression or unacceptable toxicity
- Intra-patient dose-escalation allowed after Week 5





BASELINE DISEASE CHARACTERISTICS (DOSE-ESCALATION)

	All doses N = 25
Age (years), median (min; max)	71 (42; 90)
MF/SS CTCL type, n (%)	
Mycosis fungoides (MF)	4 (16)
Sézary Syndrome (SS)	20 (80)
Non MF/SS CTCL type, n (%)	
CD4 ⁺ T-cell lymphoma, NOS	1 (4)
Clinical stage at study entry (MF/SS), n (%)	
IB	1 (4)
IIB	3 (12)
IVA1	20 (80)
No. of regimen (systemic) received, median (min; max)	4 (2; 10)



SUMMARY OF ADVERSE EVENTS (AE) (DOSE-ESCALATION)

N = 25	Total	Grade 3	Grade 4
DLT	0	-	-
AE	23 (92%)	6 (24%)	2 (8%)
Related AE	13 (52%)	2 (8%)	-
SAE	8 (32%)	2 (8%)	2 (8%)
Related SAE	2 (8%)^{††}	-	-
AE causing treatment discontinuation	1 (4%)	1 (4%)*	-
Fatal AE	2 (8%)**		

n is the number of subjects having the given event, or an event in the given category at least once

DLT: Dose limiting Toxicity; (S)AE: (Serious) Adverse Event

†† Two patients had possibly related SAE: (i) one had grade 2 atrial flutter diagnosed by ECG without clinical symptoms. The patient was known for cardiac arrhythmia. The patient received 15 more administrations without reoccurrence of atrial flutter, (ii) one other patient had hepatitis occurring 6 weeks after last administration and treatment discontinuation due to PD. Considered unlikely to be related to IPH4102 by expert hepatologist.

* One patient discontinued treatment due to general malaise in context of disease progression.

** Two patients had fatal AE: (i) one unrelated death to S. aureus sepsis, (ii) one death caused by possibly related SAE of hepatitis (see ††).



ADVERSE EVENTS RELATED TO DRUG (DOSE-ESCALATION) (REPORTED BY ≥ 2 PATIENTS, DATA CUTOFF 5/SEPT/2017)

	Related AE (N = 25)		
	All grades* n (%)	Grade 3 n (%)	Grade 4 n (%)
Any related AE	13 (52)	3 (8)	0
Lymphopenia	4 (16)	2 (8)	0
Asthenia	3 (12)	0	0
Nausea	2 (8)	0	0
Chills	2 (8)	0	0
Pyrexia	2 (8)	0	0
Arthralgia	2 (8)	0	0
Muscle spasm	2 (8)	0	0

n is the number of subjects having the given event, or an event in the given category at least once



EFFICACY OUTCOME (DOSE-ESCALATION) DATA CUT-OFF 5/SEPT/2017

	Best Response in all patients Global N=25	Best Response in Sézary Syndrome patients		
		Global n=20	Skin n=20	Blood n=20
Best Response (n)				
CR	1	1	2	5
PR	10	9	10	8
SD	12	8	8	6
PD	2	2	0	1
ORR	44 %	50 %	60 %	65 %
ORR4, n (%)	9 (36%)	8 (40%)		
DOR (days) - median (min – max)	251 (8.2 months) (64 – 519+)	302 (9.9 months) (64 – 519+)	ORR: Overall Response Rate ORR4: Rate of responses lasting ≥4 m	
PFS (days) - median (min – max)	299 (9.8 months) (28 – 610+)	329 (10.8 months) (28 – 610+)	PFS: Progression-Free Survival DOR: Duration of Response	

ORR: Overall Response Rate
ORR4: Rate of responses lasting ≥4 mo
PFS: Progression-Free Survival
DOR: Duration of Response

- > Results for 25 patients (20 SS) treated with doses ranging from 0.0001 to 10 mg/kg
- > All clinical responses are confirmed; 4 responses ongoing (DOR range 104 – 519 days)
- > Median study follow-up time, 458 days (15 months)




MSWAT (MODIFIED SEVERITY WEIGHTED ASSESSMENT TOOL) IS USED TO MEASURE SKIN TUMOR BURDEN IN MF/SS

- Two assessments
 1. Lesion assessment – patch, plaque or tumor
 2. Body surface area involved
- Calculate body surface area affected by patch, plaque and tumor
- This is then multiplied by 1, 2, or 4 for patch, plaque and tumor respectively
- The sum of these 3 values is added and an overall SWAT value between 0-400 is achieved

$$\%BSA \text{ patch} + 2(\% \text{ BSA plaque}) + 4(\% \text{ BSA tumor}) = mSWAT/400$$



MAXIMUM PERCENT CHANGE IN MSWAT SCORE AND ABERRANT BLOOD CELL COUNTS IN SÉZARY SYNDROME PATIENTS





REPRESENTATIVE PICTURES OF RESPONDERS

- **Patient 11-005:**

- > 77-year old female
- > Sézary Syndrome (SS) diagnosed in NOV 2008
- > 6 lines of previous therapies (incl. ECP + BEX + $\text{INF}\alpha$, MTX, mogamulizumab, ECP + $\text{INF}\alpha$ + MTX, romidepsin, BEX+ $\text{INF}\alpha$)
- > Started at 0.05 mg/kg on 25JAN16
- > Global PR since W10 (0.05 mg/kg), sustained at W64



Screening



W64 sustained PR




EXPLORATORY/PHARMACODYNAMICS ENDPOINTS

SKIN & BLOOD ASSESSMENTS / PT 11-005


% of KIR3DL2⁺ cells in skin lesions by IHC

SCR = screening



CD4/8 ratio in skin	mSWAT score
SCR: 49	SCR: 82.5
W5: 19	W5: 87
	W10: 36.5 <u>PR</u>
W14: 9	W14: 19.3 <u>PR</u>

- Treated skin lesions show decrease in CD4 and increase in CD8 lymphocytes
- Decrease in %KIR3DL2⁺ CD4 T-cells in skin/blood
- Sharp decrease in circulating Sézary cells in flow cytometry





REPRESENTATIVE PICTURES OF RESPONDERS


- **Patient 11-024:**

- > 75-year old male
- > SS diagnosed in AUG 2011
- > 6 lines of previous therapies (incl. MTX, INF α , vorinostat then mogamulizumab, BEX, pembrolizumab)
- > Started at 3 mg/kg on 16OCT16
- > Global PR since W14 (3 mg/kg), sustained PR at W28

Screening




W28 Sustained PR





SIGNIFICANT PRURITUS IMPROVEMENT BY VAS SCORE



VAS: Visual Analogue Scale



IPH4102-101 SUMMARY (DOSE ESCALATION) SAFETY, CLINICAL ACTIVITY AND BIOMARKERS

- IPH4102 Maximal Tolerated Dose was not reached: Recommended Ph 2 Dose is 10 mg/kg
- Well-tolerated in heavily pretreated (med. 4 prior lines) advanced CTCL patients
- Best global ORR is 44% in the overall population and 50% in SS
 - > In the Sézary population, median Duration of Response is 9.9 months and median PFS 10.8 months
- Pruritus is substantially improved in those with global response or stable disease
- Pharmacodynamic endpoints (monitoring of KIR3DL2-positive cells) are consistent with clinical activity results, confirming prompt elimination of neoplastic cells in skin and in blood

Expansion cohorts (SS, tMF) started accruing in July 2017 at the flat dose of 750 mg



ACKNOWLEDGEMENTS

Depts of Dermatology & Pathology
St Louis Hospital (Paris, France)
Martine Bagot
Caroline Ram-Wolff
Steve Mathieu
Maxime Battistella

INSERM Unit 976 (Paris, France)
Anne Marie-Cardine
Nicolas Thonnart
Armand Bensussan

Histalim (Montpellier, France)
Laurence Maunier

Leiden University Medical Center
(Leiden, Netherlands)
Maarten Vermeer

Guy's and St Thomas' Hospital
(London, UK)
Sean Whittaker

All our patients and their families...

Stanford Cancer Institute (CA, USA)
Youn H. Kim
Michael Khodadoust

Ohio State University (OH, USA)
Basem William

SKCC at Jefferson, Philadelphia (PA, USA)
Pierluigi Porcu

MDACC (TX, USA)
Madeleine Duvic
Auris Huen

Innate Pharma (Marseille, France)	
Korinna Pilz	Christine Paiva
Carine Paturel	Cécile Bonnafous
Agnès Widemann	Arnaud Dujardin
Frédérique Moriette	Ariane Morel
Lydie Lagache	Christian Belmant
Robert Zerbib	Anne T. Martin
Hatem Azim	Hélène Sicard



NEXT GENERATION IO

3 STRATEGIC KEY PILLARS

1

**NK cells
checkpoints
(NKCP)**

monalizumab
(target: NKG2A)

2

**Tumor
targeting
(TA_g)**

3

**Tumor
Microenvironment
(TME)**



MONALIZUMAB COMBINATION STRATEGY OPPORTUNITY



Mohammed Dar
VP Oncology clinical development

AstraZeneca MedImmune



NEXT-GENERATION IMMUNO-ONCOLOGY AT ASTRAZENECA/MEDIMMUNE BROAD IO CLINICAL PROGRAM TO ENHANCE ANTI-TUMOR IMMUNITY


Prime new response

TLR 7/8	HDAC ¹
DNA vaccine	HPVE7 ¹



Potentiate existing response

PD-L1	hOX40 ²	PD-1
CTLA-4	GITR	NKG2A



Reverse local immune-suppression

CD73	A2AR	CXCR2
STAT3	IDO ¹	IMCgp100 ¹
CSF-1R ¹	TGFβR-1 ¹	CCR4 ¹

Ongoing *Imfinzi* combination

1. Clinical collaborations.
2. Combination with *Imfinzi* and tremelimumab.




Monalizumab




MONALIZUMAB (IGG₄ ANTI-NKG2A)

BLOCKS NKG2A/HLA-E MEDIATED SUPPRESSION OF NK CELLS AND CD8 T CELLS

HLA-E on tumor cells



NKG2A on TILs





* underestimated because of few stroma in 5 tumors

- Score 3: > 76% positive cells
- Score 2: from 34 to 66% positive cells
- Score 1: between 1 and 33% positive cells
- Score 0: No positive cells



RATIONALE FOR DURVALUMAB & MONALIZUMAB COMBINATION: ENHANCE ANTI-TUMOR IMMUNITY BY NON-REDUNDANT, POTENTIALLY SYNERGISTIC PATHWAYS





MONALIZUMAB – DEVELOPMENT STRATEGY

ADDRESS SIGNIFICANT MEDICAL NEEDS

1

Potentiate existing responses – IO sensitive tumors

2

Reverse resistance to CPI – IO sensitive tumors


3

Unlock activity of NK and T cells – IO resistant tumors



MONALIZUMAB – JOINT CLINICAL DEVELOPMENT PLAN

FOCUS ON COMBINATIONS






MONALIZUMAB – CLINICAL DEVELOPMENT PLAN

ONGOING PHASE 1 STUDY, DURVALUMAB + MONALIZUMAB

Data snapshot 09Feb2018. Database is open and data cleaning in progress; results subject to change

Dose-Escalation



Dose Expansion



Increasingly IO-resistant

Safety Summary

- Planned dose-escalation completed without reaching MTD; no DLT reported
- Overall safety profile generally comparable to durvalumab monotherapy



MONALIZUMAB – CLINICAL DEVELOPMENT PLAN

MONALIZUMAB & CETUXIMAB COMBINATION

Rationale

- High level of HLA-E expression in SCCHN
- Cetuximab is approved in SCCHN, including in post-platinum setting
- Cetuximab-mediated ADCC is inhibited by HLA-E expression and this inhibition can be circumvented with anti-NKG2A treatment
- Combination of monalizumab and cetuximab might provide greater antitumor activity than either drug alone



Evaluate safety and define MTD/RP2D of mona+cetux



Assess antitumor activity of mona+cetux in 2L+ SCCHN

Ongoing

Explore additional combinations of mona+cetux

Planned




KEY DEVELOPMENT QUESTIONS FOR MONALIZUMAB



**Understand which
pts likely to benefit
from Mona+Durva**



**Assess potential to
combine with
chemotherapy**



**Understand potential
with tumor-targeting
mAbs**

Ongoing analysis of paired tumor and blood samples

Consider chemotherapy combination arms

Explore cetuximab-based combos




MARKET POTENTIAL AND PIPELINE NEWSFLOW

MONDHER MAHJOUBI
CHIEF EXECUTIVE OFFICER



INNATE PHARMA – PIPELINE


BUILDING AN INNOVATIVE & DIFFERENTIATED PIPELINE



Adapted from Hedge et al., Clin Cancer Res, 2016




IPH4102 – TARGETING T-CELL LYMPHOMA SÉZARY AS THE ENTRY POINT





IPH4102 – COMMERCIAL OPPORTUNITY

SIGNIFICANT POTENTIAL BEYOND SÉZARY




Epidemiology data : Internal best current estimates of patient numbers based on external research



MONALIZUMAB – COMBINATION STRATEGY

LEVERAGE NON REDUNDANT & SYNERGISTIC PATHWAYS

Potentiate responses in IO
sensitive tumors
SCCHN




Mona + Cetux **3L***

Mona + Cetux + **SoC** **2L**

Mona + Cetux + **RT/CT** **LA**

Unlock responses in IO
resistant tumors
CRC



Mona + Durva **2-4L**

Mona + Durva + **CT**

***3L: Potential fast to market opportunity**



MONALIZUMAB – COMMERCIAL OPPORTUNITY

SCCHN – CURRENT COMPETITIVE LANDSCAPE

IO SOC

Other SOC

Resectable 35k*		Unresectable 40k*	Metastatic 1L 65k*	2L 25k*
Adjuvant CT/RT	Cis-ineligible	Cetuximab + RT 40%	CT + Cetuximab	IO Mono
	Cis-eligible	Cisplatin + RT 60%		

*Drug-treated patients in US/5EU/Jpn & China in 2023. China assumes 20% access to novel therapies
Epidemiology data : Internal best current estimates of patient numbers based on external research




MONALIZUMAB – COMMERCIAL OPPORTUNITY

SCCHN – FUTURE COMPETITIVE LANDSCAPE

IO SOC

Other SOC




*Drug-treated patients in US/5EU/Jpn & China in 2023. China assumes 20% access to novel therapies
Epidemiology data : Internal best current estimates of patient numbers based on external research



MONALIZUMAB – COMMERCIAL OPPORTUNITY

CRC - THE NEXT BIGGEST OPPORTUNITY

- Third most common cancer worldwide
- ~1.1m deaths by 2030
- High unmet need in the metastatic setting
- Chemo + Bev or Cetux is SoC
- Limited options in late lines
- IO monotherapy approved in 3L MSI-high
- Large majority of patients are MSS and do not benefit from single agent IO
- Low efficacy bar in 3L



Nature Reviews | Drug Discovery

➔ Increase EGFR / PD1-PDL1 IO share



IPH5401– UNLOCK THE IMMUNE RESPONSE IN COMBINATION WITH ANTI PD/PD-L1



Reverse IO resistance



Enhance IO response



Expand into IO
refractory tumors



Tumor types	Incidence *	C5aR expression
NSCLC	290K	~80%
UCC	50K	~70%

HCC	110K	~70%
-----	------	------

CRC	575K	60%
Gastric	258K	30-35%
TNBC	72K	13-27%
Prostate	621K	35%

* US/5EU & Japan

**drug treated 1st line patients, all stages, US & EU5

Epidemiology data : Internal best current estimates of patient numbers based on external research



IPH5401 – COMMERCIAL OPPORTUNITY

NSCLC – TREATING IO FAILURES



- ~1.6m global lung cancer deaths
- IO transforming NSCLC management
- Vast majority of patients still fail IO



IO-pretreated patients

Stage III-IV NSCLC*

2nd line

US: 127k
EU5: 100k
Japan: 43k

260k
Patients
eligible

3rd line

US: 53k
EU5: 40k
Japan: 17k

110k
Patients
eligible


IO-pretreated NSCLC

* ~ 70% 1st line patients treated with IO based regimen



IPH5401 – COMMERCIAL OPPORTUNITY

HCC – OPTIMIZING IO RESPONSE



- **>500,000** people affected
- Third leading cause of cancer deaths
- Moderate activity of CPI



IO-naïve patients

Advanced stage HCC*

1st line

US: 5k
EU5: 10k
Japan: 10k

25k
Patients
treated

2nd line

US: 5k
EU5: 5k
Japan:

13k
Patients
treated

* IO likely to become the standard of care in 1st line



INNATE PHARMA – LONG TERM CATALYSTS

			IPH52 Ph 1	IPH52 combo Ph 1/2		IPH52 potential pivotal program*
	IPH5401 + Durva Ph1/2	IPH5401 + PD1/L1 Ph2-3 rd indication	IPH43 Ph 1/2	IPH5401 potential pivotal program*	IPH43 Ph 2/3	IPH43 potential pivotal program*
		IPH4102 Pivotal-SS	IPH4102 Ph 1/2 ATLL	IPH4102 Pivotal-ATLL		
		IPH4102 Pivotal-CTCL	IPH4102 Ph1/2-PTCL	IPH4102 Pivotal-PTCL		
Mona + Durva + CT Ph 1/2	Mona + Durva Ph2-SCCHN	Mona potential pivotal program*				
H1-2018	H2-2018	2019	2020	2021	2022	2023+
Mona + Cetux SCCHN	Mona + Cetux SCCHN update	Mona + Durva + CT Ph1/2	Mona + Durva Ph2-SCCHN	Mona potential pivotal program*	Mona Potential BLA*	
Mona + Durva*	Mona + Durva Other tumors*	Mona + Cetux Mona + Durva Update				IPH4102 Pivotal-ATLL
	IPH4102 cohort expansion in SS		IPH4102 Pivotal - SS	IPH4102 SS Potential BLA*	IPH4102 Pivotal-CTCL	IPH4102 Pivotal-PTCL
		IPH5401 + Durva Ph1	IPH5401 + Durva Ph1/2	IPH43 Ph 1		IPH5401 potential pivotal program*
			IPH5401 + PD1/L1 Ph2-3 rd indication	IPH52 Ph 1		IPH52 combination Ph 1/2
						IPH4102 CTCL, ATLL, PTCL Potential BLA*
						IPH5401 Potential BLA*

- First Patient In
- Data read out
- Potential BLA

* Subject to data/governance decision



UPCOMING CONFERENCE AACR 2018

INNATE PHARMA TO PRESENT NEW DATA FROM ITS IMMUNO-ONCOLOGY PORTFOLIO

- **Oral presentation of Eric Vivier, CSO, on next generation immunotherapies**
- **5 presentations by Innate Pharma teams, including:**
 - > Preliminary clinical efficacy data on monalizumab in combination with cetuximab in R/M SCCHN
 - > 2 posters on preclinical data supporting the rationale for the development of monalizumab in combination with cetuximab or durvalumab
 - > 1 poster on anti-CD39/anti-73 antibody programs targeting the adenosine pathway
 - > 1 poster on new antibody anti-Siglec-9
- Preclinical abstracts will be available on AACR website after March 14, 2018



QUESTIONS & ANSWERS



CLOSING REMARKS

MONDHER MAHJOUBI
CHIEF EXECUTIVE OFFICER



KEY MESSAGES

World-class science and technology platform

Clinical read-outs ahead for monalizumab and IPH4102 programs


Delivering on IPH5401 with clinical collaborations to accelerate development

Potential to address large unmet medical needs in cancer

Financial strength, enabling room for investment




INNATE PHARMA – OUR AMBITION BUILDING IO LEADERSHIP



Disciplined execution

THE INNATE IMMUNITY COMPANY



THANK YOU

